Vaginal Drug Delivery


The vagina has been studied as a favorable  site for the local and systemic delivery  of drugs and this route offers certain  advantages, such as avoidance of gut and  hepatic first pass metabolism, reduction  in gastrointestinal and hepatic side effects,  and local targeting of drugs to the  reproductive organs. Vaginally administered  agents and formulations are mainly  being developed to provide “dual prophylaxis”  for contraception and protection  against microbial infections including AIDS  and other sexually transmitted diseases  (STDs). Drug delivery technologies that  have been used for vaginal drug delivery  include the intravaginal ring (IVR) and  VagiSite bioadhesive technology.


    Related Conference of Vaginal Drug Delivery

    February 24-25, 2025

    2nd International Conference on Pharmacognosy

    Madrid, Spain
    February 27-28, 2025

    8th International on Pharmacy and Pharmaceutical Conference

    Prague, Czech Republic
    March 10-11, 2025

    35th Annual European Pharma Congress

    Rome, Italy
    April 14-15, 2025

    18th European Biosimilars Congress

    Paris, France
    April 24-25, 2025

    18th World Drug Delivery Summit

    London, UK
    May 05-06, 2025

    19th World Drug Delivery Summit

    Vancouver, Canada
    June 16-17, 2025

    3rd Global Online Summit on Nanoscience and Nanotechnology

    Zurich, Switzerland
    June 23-24, 2025

    38th World Congress on Pharmacology

    Aix-en-Provence, France
    September 23-24, 2025

    10th International Conference on Future Pharma and Innovations

    Amsterdam, Netherlands
    November 27-28, 2025

    4th World Conference on Pharma Industry and Medical Devices

    Zurich, Switzerland
    November 27-28, 2025

    4th World Congress on Precision and Personalized Medicine

    Zurich, Switzerland

    Vaginal Drug Delivery Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in